CORRECT THE GENETIC BURDEN COVER An estimated of 495,000 infants are born each year in India with congenital malformations, 21,400 with Down syndrome, 9,000 with thalassemia, 5,200 with sickle cell disease, and 9,760 with amino acid disorders. Currently the diagnostic and rehabilitation facilities are scarce and focused in certain limited locations but the effects of these diseases are immense. Research shows that Genetic and congenital abnormality in India is the second most common cause of infant and childhood mortality and occurs with a prevalence of 25-60 per 1000 births. The growing burden of Genetic Disorders may be multifactorial in origin, comprising of climate changes, environmental pollution, later age for conceiving a baby, hectic lifestyles etc. But this can be curbed by making genetic testing centres easily accessible for expecting couples as and when needed. Currently, government has adopted universal screening for Congenital Hearing Deficit in the state of Kerala. Also, Goa Government had started the universal screening for all newborns for Congenital Metabolic Problems. But similar programmes are needed across the country to deal with the outset as early as possible. 20
The BioSpectrum India edition was launched in March 2003 and is India's first comprehensive biotech business monthly magazine. It provides comprehensive coverage of the exciting happenings in life sciences, which include BioPharma, BioAgriculture, BioInformatics, BioIndustrial, BioSuppliers and BioServices and show cases the emerging Indian entrepreneurships in biotech industry. In a short time BioSpectrum has emerged as the most preferred platform to engage the life sciences industry in India and Asia Pacific. It is also widely accepted by research and academia community. Top key policy makers in the Central and state government use the magazine as a platform to reach out the Indian Biotech Industry. BioSpectrum has columns by Indian's top policy makers, biotechnology professionals, scientists and NGOs. Readers of BioSpectrum are from among the key Policy Makers, Key Executives and the Influencer's in Biotechnology, Pharmaceutical Companies, Research Heads of Clinical Research, Clinical Trials and Contract Mfg Organizations, Educational Institutes, Consultants, Fund Managers etc
